BioCentury
ARTICLE | Clinical News

Selumetinib: Phase I data

June 1, 2015 7:00 AM UTC

Data from 41 patients with solid tumors in an open-label, dose-escalation, UK Phase I trial showed that once-daily oral vandetanib plus oral selumetinib led to 4 cases of stable disease in patients wi...